Cover Image

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

Saved in:
Bibliographic Details
Main Authors: Huber, Henriette (Author) , Tausch, Eugen (Author) , Schneider, Christof (Author) , Edenhofer, Simone (Author) , Tresckow, Julia von (Author) , Robrecht, Sandra (Author) , Giza, Adam (Author) , Zhang, Can (Author) , Fürstenau, Moritz (Author) , Dreger, Peter (Author) , Ritgen, Matthias (Author) , Illmer, Thomas (Author) , Illert, Anna Lena (Author) , Dürig, Jan (Author) , Böttcher, Sebastian (Author)
Format: Article (Journal)
Language:English
Published: 14 September 2023
In: Blood
Year: 2023, Volume: 142, Issue: 11, Pages: 961-972
ISSN:1528-0020
DOI:10.1182/blood.2023020013
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2023020013
Get full text
Author Notes:Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Fürstenau, Peter Dreger, Matthias Ritgen,Thomas Illmer, Anna Lena Illert, Jan Dürig,Sebastian Böttcher [und 10 weitere Personen]
Description
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood.2023020013

Similar Items